An adjuvant approach to Cancer therapy:

Innovation through simplification ...

Advantagene:  Making the “Standard of Care” for cancer work better

Pictorial:  Lung tissue of mice treated for a remotely located tumor.  The cancerous growth on the lungs shows metastatic reach away from the tumor.  PBS depicts where a placebo treatment was used on the primary tumor, XRT depicts where the remote tumor had radiation treatment alone, TK depicts where the tumor was treated using AdV-tk alone, and TKR shows the remote effect of Advantagene's adjuvant GMCI™ approach to cancer therapy.  Note the metastatic impact of the GMCI™ approach away from the primary tumor.

Local anticancer therapies, like surgery and radiation, are ineffective if they fail to eradicate every tumor cell and cannot be used in the treatment of metastasis.  Chemotherapy is often limited by systemic toxicity.  

Advantagene’s GMCI™ approach does not replace the current standard of care, but instead works with current therapies for a targeted approach.  In addition GMCI™ offers the goal of engaging the immune system to prevent and attack metastisis.   

Additional preclinical studies were conducted to evaluate the use of AdV-tk in conjunction with surgery, chemotherapy and radiation therapy. These studies led to identification of novel properties of AdV-tk and synergistic effects with standard anti-cancer therapies.  Principal among the discoveries were the increased local and systemic anti-tumor effects of the GMCI™ approach (treatment as additive to the standard of care).